-
- David E. Trentham
- Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
-
- Roselynn A. Dynesius-Trentham
- Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
-
- E. John Orav
- Department of Medicine, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA 02115.
-
- Daniel Combitchi
- Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
-
- Carlos Lorenzo
- Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
-
- Kathryn Lea Sewell
- Division of Rheumatology, Department of Medicine, Beth Israel Hospital, the Charles A. Dana Research Institute, the Harvard-Thorndike Laboratory, Harvard Medical School, Boston, MA 02215.
-
- David A. Hafler
- Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
-
- Howard L. Weiner
- Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
抄録
<jats:p>Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.</jats:p>
収録刊行物
-
- Science
-
Science 261 (5129), 1727-1730, 1993-09-24
American Association for the Advancement of Science (AAAS)
- Tweet
キーワード
詳細情報
-
- CRID
- 1363670318670823040
-
- NII論文ID
- 80007268746
-
- ISSN
- 10959203
- 00368075
-
- データソース種別
-
- Crossref
- CiNii Articles